Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects

References

• Ackland J, Ratter S, Bourne G, Rees LH. 1983. Pro-opiomelanocortin peptides in the human fetal pituitary. Regul Pept 6:51–61.
   Google Scholar
• Alberti G, Zimmet P, Shaw J, Grundy SM. 2006. The IDF consensus worldwide definition of the metabolic syndrome. In: Federation ID, editor. Brussels: IDF Communications.
   Google Scholar
• Acher R, Chauvet J. 1988. Structure, processing and evolution of the neurohypophysial hormone-neurophysin precursors. Biochimie 70:1197–1207.
   Google Scholar
• Arlt W, Stewart PM. 2005. Adrenal corticosteroid biosynthesis, metabolism, and action. Endocrinol Metab Clin N Am 34:293–313, viii.
   PubMed Web of Science ®Google Scholar
• Banki CM, Bissette G, Arato M, O'Connor L, Nemeroff CB. 1987. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry 144:873–877.
   PubMed Web of Science ®Google Scholar
• Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. 2006. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 6:3414–3425.
   PubMed Web of Science ®Google Scholar
• Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 57:289–300.
   Web of Science ®Google Scholar
• Birkenkamp-Demtroder K, Wagner L, Brandt Sorensen F, Bording Astrup L, Gartner W, Scherubl H, et al. 2005. Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology 82:121–138.
   Google Scholar
• Brunelin J, d'Amato T, van Os J, Cochet A, Suaud-Chagny MF, Saoud M. 2008. Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophr Res 100:206–211.
   Google Scholar
• Bushe C, Holt R. 2004. Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia. Br J Psychiatry Suppl 47:S67–71.
   PubMedGoogle Scholar
• Ciaraldi TP, Mudaliar S, Barzin A, Macievic JA, Edelman SV, Park KS, et al. 2005. Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J Clin Endocrinol Metab 90:352–358.
   Google Scholar
• Clark C, Kopala L, Li DK, Hurwitz T. 2001. Regional cerebral glucose metabolism in never-medicated patients with schizophrenia. Can J Psychiatry 46:340–345.
   PubMed Web of Science ®Google Scholar
• D'Agostino RB. 1986. Tests for Normal Distribution. In: D'Agostino RB, Stepenes MA, editors. Goodness-of-fit techniques. New York: Marcel Decker.
   Google Scholar
• Dai T, Patel-Chamberlin M, Natarajan R, Todorov I, Ma J, LaPage J, et al. 2009. Heat shock protein 27 overexpression mitigates cytokine-induced islet apoptosis and streptozotocin-induced diabetes. Endocrinology 150:3031–3039.
   Google Scholar
• Engelmann M, Landgraf R, Wotjak CT. 2004. The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol 25:132–149.
   PubMed Web of Science ®Google Scholar
• Friedland JS, Shattock R, Remick DG, Griffin GE. 1993. Mycobacterial 65-kD heat shock protein induces release of proinflammatory cytokines from human monocytic cells. Clin Exp Immunol 91:58–62.
   PubMed Web of Science ®Google Scholar
• Gartner W, Lang W, Leutmetzer F, Domanovits H, Waldhausl W, Wagner L. 2001. Cerebral expression and serum detectability of secretagogin, a recently cloned EF-hand Ca(2 +)-binding protein. Cereb Cortex 11:1161–1169.
   PubMed Web of Science ®Google Scholar
• Gerozissis K. 2008. Brain insulin, energy and glucose homeostasis; genes, environment and metabolic pathologies. Eur J Pharmacol 585:38–49.
   PubMed Web of Science ®Google Scholar
• Goldman MB, Robertson GL, Luchins DJ, Hedeker D. 1996. The influence of polydipsia on water excretion in hyponatremic, polydipsic, schizophrenic patients. J Clin Endocrinol Metab 81:1465–1470.
   PubMed Web of Science ®Google Scholar
• Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A, et al. 2010. Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15:118–119.
   PubMed Web of Science ®Google Scholar
• Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, et al. 2011. Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology. 2011 Aug;36(7):1092–1096
   PubMed Web of Science ®Google Scholar
• Heinrichs M, von Dawans B, Domes G. 2009. Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol 30:548–557.
   PubMed Web of Science ®Google Scholar
• Hession C, Osborn L, Goff D, Chi-Rosso G, Vassallo C, Pasek M, et al. 1990. Endothelial leukocyte adhesion molecule 1: direct expression cloning and functional interactions. Proc Natl Acad Sci USA 87:1673–1677.
   PubMed Web of Science ®Google Scholar
• Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D, et al. 2008. Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 13:1118–1128.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Lee SJ, Toh KY, Lee CU, Lee C, Paik IH. 2001. Identification of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia. Schizophr Res 52:127–135.
   PubMed Web of Science ®Google Scholar
• Koller EA, Doraiswamy PM. 2002. Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841–852.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy D, Levin Y, Harris L, Umrania Y, Bahn S, Guest PC. 2011. Analysis of the human pituitary proteome by data independent label-free liquid chromatography tandem mass spectrometry. Proteomics 11:495–500.
   Google Scholar
• Kwiterovich Jr PO. 2000. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 86(12A):5L–10L.
   Google Scholar
• Mai JK, Berger K, Sofroniew MV. 1993. Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J Hirnforsch 34:133–154.
   PubMedGoogle Scholar
• Martins-de-Souza D, Wobrock T, Zerr I, Schmitt A, Gawinecka J, Schneider-Axmann T, et al. 2010. Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls. World J Biol Psychiatry 11:719–728.
   PubMed Web of Science ®Google Scholar
• McDermott E, de Silva P. 2005. Impaired neuronal glucose uptake in pathogenesis of schizophrenia – can GLUT 1 and GLUT 3 deficits explain imaging, post-mortem and pharmacological findings?. Med Hypotheses 65:1076–1081.
   PubMedGoogle Scholar
• McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, et al. 2008. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 372:224–233.
   PubMed Web of Science ®Google Scholar
• Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, et al. 2008. 38. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101:273–86.
   PubMed Web of Science ®Google Scholar
• Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al. 2009. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 66:1013–1022.
   PubMed Web of Science ®Google Scholar
• Montaner J, Perea-Gainza M, Delgado P, Ribo M, Chacon P, Rosell A, et al. 2008. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 3:2280–2287.
   Google Scholar
• Onat A, Hergenc G, Sansoy V, Fobker M, Ceyhan K, Toprak S, et al. 2003. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. Atherosclerosis 168:81–89.
   PubMed Web of Science ®Google Scholar
• Osby U, Correia N, Brandt L, Ekbom A, Sparen P. 2000. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45:21–28.
   PubMed Web of Science ®Google Scholar
• Papadimitriou A, Priftis KN. 2009. Regulation of the hypothalamic-pituitary-adrenal axis. Neuroimmunomodulation 16:265–271.
   PubMed Web of Science ®Google Scholar
• Pariante CM, Vassilopoulou K, Velakoulis D, Phillips L, Soulsby B, Wood SJ, et al. 2004. Pituitary volume in psychosis. Br J Psychiatry 185:5–10.
   PubMed Web of Science ®Google Scholar
• Prohaszka Z, Fust G. 2004. Immunological aspects of heat-shock proteins-the optimum stress of life. Mol Immunol 41:29–44.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Thakore JH. 2002. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 71:239–257.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Collins P, Thakore JH. 2003. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–289.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Sharifi N, Condren R, Thakore JH. 2004. Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 29:1065–1070.
   PubMed Web of Science ®Google Scholar
• Schousboe I. 1985. beta 2-Glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 66:1086–1091.
   PubMed Web of Science ®Google Scholar
• Schwarz MJ, Riedel M, Gruber R. 1999. Ackenheil M, Muller N. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am J Psychiatry 156:1103–1104.
   PubMed Web of Science ®Google Scholar
• Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG. 2000. Central nervous system control of food intake. Nature 404, 661–671.
   PubMed Web of Science ®Google Scholar
• Silva JC, Denny R, Dorschel CA, Gorenstein M, Kass IJ, Li GZ, et al. 2005. Quantitative proteomic analysis by accurate mass retention time pairs. Anal Chem 77:2187–2200.
   PubMed Web of Science ®Google Scholar
• Skovhus KV, Bergholdt R, Erichsen C, Sparre T, Nerup J, Karlsen AE, et al. 2006. Identification and characterization of secretagogin promoter activity. Scand J Immunol 64: 639–645.
   Google Scholar
• Swatton JE, Prabakaran S, Karp NA, Lilley KS, Bahn S. 2004. Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE). Mol Psychiatry 9:128–143.
   PubMedGoogle Scholar
• Takahashi T, Suzuki M, Velakoulis D, Lorenzetti V, Soulsby B, Zhou SY, et al. 2009. Increased pituitary volume in schizophrenia spectrum disorders. Schizophr Res 108:114–121.
   Google Scholar
• Tsigos C, Chrousos GP. 2002. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 53:865–871.
   PubMed Web of Science ®Google Scholar
• van der Weerd L, Tariq Akbar M, Aron Badin R, Valentim LM, Thomas DL, Wells DJ, et al. 2010. Overexpression of heat shock protein 27 reduces cortical damage after cerebral ischemia. J Cereb Blood Flow Metab 30:849–856.
   PubMed Web of Science ®Google Scholar
• von Eckardstein A, Holz H, Sandkamp M, Weng W, Funke H, Assmann G. 1991. Apolipoprotein C-III(Lys58––Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest 87:1724–1731.
   Google Scholar
• Walsh P, Spelman L, Sharifi N, Thakore JH. 2005. Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 30:431–437.
   Google Scholar
• Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z, et al. 2006. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 78:3571–3576.
   PubMed Web of Science ®Google Scholar
• Zhan X, Evans CO, Oyesiku NM, Desiderio DM. 2003. Proteomics and transcriptomics analyses of secretagogin down-regulation in human non-functional pituitary adenomas. Pituitary 6:189–202.
   Google Scholar